 To deterime the efficacy of 500 μg and 300 μg darbepoetin alfa administered subcutaneously SC on an every 3 weeks Q3W schedule, and the effect of intravenous IV iron supplementation in the treatment of anemia in patients with non-myeloid malignancies who were receiving multicycle chemotherapy. 